SAN DIEGO—Omitting adjuvant tamoxifen may not put women aged older than 65 years with early-stage breast cancer at increased risk for local or distant disease recurrence, according to a large, retrospective study presented at the 52nd annual meeting of the American Society for Radiation Oncology.
MILAN—The investigative poly (ADPribose) polymerase (PARP) inhibitor iniparib (BSI-021) im proved not only progression-free survival (PFS) but also overall survival (OS) in the final analysis of a randomized phase 2 study, presented at the 35th European Society for Medical Oncology Congress by Joyce O’Shaughnessy, MD, of US Oncology and Baylor Sammons Cancer Center, Houston.
SAN DIEGO—Elizabeth Brunton, RN, MSN, OCN, started in the nursing field in 1973. More than 35 years later, she is the recipient of the American Society for Radiation Oncology (ASTRO) Nurse Excellence Award. This award is presented annually to a registered nurse who goes above and beyond the normal standards of nursing practice.
This past April, Geisinger Medical Center’s (GMC) Cancer Institute became one of 14 sites added to the National Cancer Institute Community Cancer Centers Program (NCCCP). Joining this national network of community cancer centers offers GMC the opportunity to expand its state-of-the-art cancer care and research in northeast Pennsylvania.
To sign up for our newsletter or print publications, please enter your contact information below.
